Vivos Therapeutics (VVOS) EBT Margin (2020 - 2026)
Vivos Therapeutics (VVOS) reported EBT Margin of 150.77% for Q1 2026, down 2265.0% year-over-year from 6.96% in Q1 2025, and up 17.09% quarter-over-quarter from 181.85% in Q4 2025.
Vivos Therapeutics (VVOS) EBT Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of EBT Margin data on file, last reported at 150.77% in Q1 2026.
- EBT Margin for Q1 2026 came in at 150.77%, down 2265.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 128.36% (down 5115.0% YoY), and the FY2025 annual result was 121.71%, down 4724.0% from the prior year.
- EBT Margin rose to 150.77% in Q1 2026 per VVOS's latest filing, from 181.85% in the prior quarter.
- Over five years, EBT Margin peaked at 288.39% in Q4 2023 and troughed at 181.85% in Q4 2025.
- A 5-year average of 91.33% and a median of 127.98% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2024: EBT Margin jumped 44254 bps in 2023, then plunged 36641 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 154.15% in 2022, then surged by 287 bps to 288.39% in 2023, then plunged by 127 bps to 78.02% in 2024, then tumbled by 133 bps to 181.85% in 2025, then advanced by 17 bps to 150.77% in 2026.
- Business Quant data shows VVOS's EBT Margin at 150.77% in Q1 2026, 181.85% in Q4 2025, and 79.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 15.57% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 27.84% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 4.87% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 22.61% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 9.84% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 19.17% |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -150.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -150.77% |
| Dec 31, 2025 | -181.85% |
| Sep 30, 2025 | -79.61% |
| Jun 30, 2025 | -131.23% |
| Mar 31, 2025 | -128.12% |
| Dec 31, 2024 | -78.02% |
| Sep 30, 2024 | -67.77% |
| Jun 30, 2024 | -47.61% |
| Mar 31, 2024 | -110.06% |
| Dec 31, 2023 | 288.39% |
| Sep 30, 2023 | -63.41% |
| Jun 30, 2023 | -162.83% |
| Mar 31, 2023 | -44.15% |
| Dec 31, 2022 | -154.15% |
| Sep 30, 2022 | -127.98% |
| Jun 30, 2022 | -167.11% |
| Mar 31, 2022 | -146.30% |
| Dec 31, 2021 | -168.68% |
| Sep 30, 2021 | -119.95% |
| Jun 30, 2021 | -89.90% |